Eli Lilly and Company’s (LLY) “Buy” Rating Reiterated at The Goldman Sachs Group

Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reaffirmed by The Goldman Sachs Group in a report issued on Friday,MarketScreener Latest Ratings reports. They presently have a $1,283.00 target price on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 20.29% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. CICC Research raised their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Barclays boosted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,220.37.

Eli Lilly and Company Trading Up 2.4%

Eli Lilly and Company stock traded up $24.94 during trading hours on Friday, reaching $1,066.59. The company had a trading volume of 2,353,359 shares, compared to its average volume of 3,175,252. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a 50-day moving average price of $941.52 and a 200 day moving average price of $1,003.33. The firm has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a P/E/G ratio of 1.11 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the business earned $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently made changes to their positions in the company. Cidel Asset Management Inc. boosted its stake in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after buying an additional 5,591 shares during the last quarter. Spire Wealth Management raised its stake in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares during the period. Coldstream Capital Management Inc. raised its position in Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares during the period. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after purchasing an additional 5,595 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 retatrutide results, with substantial weight loss across doses and long-term durability, boosting confidence in its next major obesity franchise. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
• Positive Sentiment: Investors are also reacting to repeated coverage that retatrutide may outperform existing GLP-1 therapies, which could expand Lilly’s lead in the fast-growing weight-loss drug market. Patients on Lilly’s next-gen obesity drug lost 28% of body weight, company says
• Positive Sentiment: Jefferies raised its price target on LLY to $1,330, signaling continued analyst confidence in Lilly’s earnings power and obesity pipeline. Jefferies lifts Eli Lilly price target to 1,330 from 1,300
• Positive Sentiment: Lilly’s new late-stage Foundayo data also showed strong weight-loss results in older adults, adding more support to the company’s broader GLP-1 growth story. Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference
• Neutral Sentiment: Lilly is expanding beyond obesity through acquisitions and pipeline development, including a deal for Engage Biologics and new studies in Alzheimer’s and heart failure, which supports long-term diversification but is less immediately market-moving. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.